abstract |
The present invention describes antibody formulations comprising a mixture of non-reducing sugars, anti-α4β7 antibodies and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and can delay the degradation of anti-α4β7 antibodies therein, or exhibit any combination thereof. The present invention further provides a safe administration protocol for these antibody formulations, which is easy to follow and produces a therapeutically effective amount of anti-α4β7 antibody in vivo. |